Navigation Links
EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
Date:11/4/2007

al, personnel and insurance expenses for the nine months ended September 30, 2007 as compared to the same period in 2006.

Research and Development (R&D) Expense

R&D expense increased by $0.3 million from $4.4 million for the third quarter of 2006 to $4.7 million for the third quarter of 2007. During the 2007 quarter the company proceeded with two clinical trials of NP-1, which commenced in April 2007, prepared its response to the EMEA regarding the Day 120 List of Questions related to the Ceplene MAA and continued its Phase I clinical trial of EPC 2407. During the third quarter of 2006, the company's research and development efforts concentrated on the continuation of its Phase III clinical trial for LidoPAIN SP, the registration of Ceplene in Europe as remission maintenance therapy for AML and preparing EPC2407 for an IND filing and commencement of clinical trials.

R&D expenses decreased by $0.6 million from $12.3 million for the nine months ended September 30, 2006 to $11.7 million for the nine months ended September 30, 2007. During the nine months ended September 30, 2007, the Company's clinical activity increased significantly with the initiation of three clinical trials of NP-1 and the continuation of its Phase I clinical trial of EPC 2407. Consulting expenses also increased significantly as the company received and reviewed the EMEA's Day 80 report and the Day 120 List of Questions related to the Ceplene MAA, submitted a written response to the Day 120 List of Questions, and gave an oral presentation in September. The increase in clinical activity and consulting expense during the nine months ended September 30, 2007 was offset by a reduction in preclinical and manufacturing activity. During the nine months ended September 30, 2006, EpiCept's research and development efforts concentrated on preparing EPC2407 for an IND filing and commencement of clinical trials, the continuation of a Phase III clinical trial for LidoPAIN SP, preparation of t
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. EpiCept Accelerates Development of Phase I Clinical Study for Cancer
2. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
3. Autopsy reports could be valuable and informative
4. China reports declining number of SARS Cases
5. Russia Reports First SARS Case
6. Research reports that c-section deliveries are rising
7. Jharkhand reports 13,000 Malaria cases
8. Uganda Reports Failure To Contain Sleeping Sickness
9. WHO reports 36 million deaths world wide due to chronic diseases
10. Reports of Hantavirus infection in India raise concerns
11. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to The Madison-St. ... Pfizer Inc., Greenstone LLC and Pfizer R&D Cortex District ... defects as a result of using Zoloft during ... filed in St. Clair County Circuit Court (Case No. ... the defendant companies allegedly concealed the risks of serious ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Until now, ... (relational tables) or unstructured data (document stores). SQL products ... products have basically managed the wide assortment of unstructured ... to work with Big Data is with a NoSQL ... the various aspects of all Big Data issues. ...
(Date:8/28/2014)... August 29, 2014 Career Step, an ... released a new video designed to help students and ... coding and billing field. The video details what medical ... for these professionals, and the education requirements for entering ... option that’s often overlooked when people are considering a ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 When David ... and long-time friend of Mark Brnovich, was asked to ... Republican nomination for the Attorney General seat in the ... quickly gathered the support of Cardinal Hall of Fame ... Cardinals Derek Kennard and Mark Walczak. Green, Kennard and ...
(Date:8/28/2014)... banker arrives at the emergency department with complaints ... alcohol every dayoften at business lunches, and at ... decided to quit drinking and had his last ... It,s a common scenario in emergency rooms across ... and develops withdrawal. , Withdrawal is a potentially ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 3Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 4Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3
... Inhibiting a protein involved in bone metabolism can delay the ... with a particular form of prostate cancer, a researcher will ... Professor Stphane Oudard, Head of ... says that his team,s research on the effects of the ...
... for prostate cancer will be unveiled at the 2011 ... Led by Dr David rsted at the Copenhagen University ... with benign prostate enlargement have an increased risk of ... shows that monitoring prostate-specific antigen levels can be used ...
... News) -- People,s bodies build up vitamin D through exposure ... live in areas of the United States with low sunlight ... who live in the same places. The researchers say ... change. "This study shows that across-the-board vitamin D recommendations just ...
... -- Although some studies have suggested that men can ... their voices, a new study appears to dispel that notion ... women are ovulating by examining changes in their voices over ... Unlike previous studies, the researchers behind the new study ...
... Chronic Disease Alliance (ECDA)1 welcomes the UN High Level Meeting ... killers. "It is a memorable day in the history ... table gives a strong sense of the burden it represents ... challenge for all nations in the world2", declared Professor Michel ...
... 23 (HealthDay News) -- New research suggests that depression ... have survived breast cancer from getting screenings that could ... "Depression can make people more inattentive to potential ... recommendations to reduce their risk," said study researcher Amelie ...
Cached Medicine News:Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 2Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 3Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 4Health News:2 new cost-effective ways to predict prostate cancer 2Health News:2 new cost-effective ways to predict prostate cancer 3Health News:2 new cost-effective ways to predict prostate cancer 4Health News:Many Black Men in Cold Climates Lack Vitamin D 2Health News:Non-communicable diseases at the center of UN discussions 2Health News:Depression After Cancer Keeps Some From Follow-Up Care 2
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... Aug. 28, 2014  A candidate Ebola vaccine could be given ... and Mali as early as September, ... aimed at preventing the disease that has killed more than 1,400 ... . Human trials of this candidate vaccine, being co-developed ... to be accelerated with funding from an international consortium in response ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7
... of its commitment to supporting efforts to improve the ... has awarded $1,000 grants to ten health care organizations ... issues. (Logo: http://photos.prnewswire.com/prnh/20100412/DA84842LOGO ) ... the 2010 Beryl Institute Patient Experience grants are: ...
... PITTSBURGH, Oct. 19 Mylan Inc. (Nasdaq: MYL ... preferred stock issuance, the company has declared its quarterly dividend ... of 6.5% and a liquidation preference of $1,000.00 per share) ... of record as of Nov. 1, 2010.  Nov. 15, is ...
Cached Medicine Technology:Patient Experience Research Grants Awarded 2Patient Experience Research Grants Awarded 3
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
9mm Gently Curved Jaws, without lock; in Titanium....
8mm angled shaft with tip at 90 degree angle wtih rounded tear drop point; Tip available in left, right and center; (Right-SQT-225 and Left -SQT-227) In Titanium....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Medicine Products: